Delivery Order SPE2DB20D3101-SPE2DB25FREP5

Award Date 3/17/25
Potential Completion Date 3/18/25
Potential Value $2.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $2,384.90, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,568,232,723 units of Doxycycline Hyclate 100 mg tablets, a common antibiotic medication. The contract is a Firm Fixed Price Delivery Order with a performance period through May 14, 2025. It is not designated as a set-aside contract, indicating open competition....
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $1,283.49 firm fixed-price delivery order is for the supply of 4,566,178,214 units of doxycycline hyclate 100 mg capsules. The contract has an ultimate completion date of October 23, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This federal contract award, valued at $2,214.00, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order (SPE2DX15D1113|SPE2DX25FBJMF) for the supply of 4,568,073,068 units of Doxycycline Hyclate 100 mg tablets. The contract is a firm fixed-price arrangement with an ultimate completion date of April 30, 2025. This award is not designated as a set-aside contract,...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract has an award value of $1,324.65 and is a delivery order with a firm fixed price pricing type. The contract is for the supply of 4,567,254,166 units of Doxycycline Hyclate 100 mg tablets, a pharmaceutical product used in medical treatment. The contract has an ultimate completion date of February 13, 2025. This...
This federal contract award is a delivery order issued to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The order, valued at $1,156.07, is for the delivery of 4,560,447,359 units of Doxycycline Hyclate 100 mg tablets. The contract has a firm fixed price and has an ultimate completion date of April 3, 2023. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,725.41 firm-fixed-price delivery order contract is for the supply of 4,560,318 units of Doxycycline Hyclate 100mg tablets. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive range of...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,567,842,809 units of Doxycycline Hyclate 100 mg tablets, with a ceiling value of $1,093.88. The contract is a Delivery Order with a Firm Fixed Price pricing type, and has an ultimate completion date of April 9, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds...
This federal contract award, with ID SPE2DB22D3501|SPE2DB23FTR82, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,559,255,906 units of doxycycline hyclate 100 mg tablets. The $1,644.16 firm-fixed-price delivery order has an ultimate completion date of December 5, 2022. This award is not associated with a set-aside program. AmerisourceBergen, through its Corporate Office division, holds significant...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,237.23, is a Firm Fixed Price Delivery Order for the supply of Doxycycline Hyclate 20 mg tablets. This award is not associated with a set-aside program. The contract is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at...
This federal contract award is for the delivery of 4,562,302,237 units of the pharmaceutical product Doxycycline Hyclate 100 mg tablets. The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract has a ceiling value of $1,157.06 and is a firm fixed-price delivery order with an ultimate completion date of September 27, 2023. The contracting agency is the Defense Logistics Agency (DLA), a defense agency....
  • SPE2DB20D3101
    Indefinite Delivery Contract
  • SPE2DB20D3101-SPE2DB25FREP5
    Delivery Order

This federal contract award, valued at $2,339.04, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order to supply 4,567,603,361 units of Doxycycline Hyclate 100 mg tablets.

The award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

In addition to the DLA contract, Amerisourcebergen also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, covering similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

Generated 6/16/25, 10:49 AM